Renée JG Arnold PharmD, RPh

Course Description

This module is an introduction to the role of cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) in medical decision making from multiple perspectives. It will describe situations in which CEA is the acceptable method of pharmacoeconomic (PE) analysis, the components included, computational methods, cost composition, effectiveness metrics [e.g., life-years saved (LYS) quality-adjusted life-years, new thrombosis avoided]; incremental vs. average cost-effectiveness ratios; primary and intermediate clinical outcomes; sensitivity analysis; absolute vs. relative values and use of CEA and CUA in medical decision making.

Learning Objectives

By the end of the Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA) module, you will be able to:

  • State the role of cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) in medical decision making.
  • Define the components of CEA and CUA.
  • Understand the computations involved in CEA and CUA.
  • Understand the concerns in attribution of cost components to a particular treatment arm.
  • Summarize the resources used in a therapy or service and assign monetary values to those resources.
  • Explain the use of applications such as Microsoft Excel and DATA™ to develop and perform CEAs and CUAs.
  • Analyze the value for money from health technologies
  • Compare and contrast different cost-utility models of human papillomavirus (HPV) vaccine, using five published HPV vaccine cost-utility models as the basis for medical decision making.
  • Summarize how CEA and CUA are used in health policy decisions regarding government approval of and reimbursement for therapies.
  • Use and apply sensitivity analyses and discounting techniques in CEA and CUA.
  • Explain how point of view and perspective affect CEA and CUA.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now